ROC Inc.

Big news for Australians facing rare ovarian cancers!

From March 1, 2026, the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) are now listed on the PBS under a world-first pan-tumour (tumour-agnostic) approval. This means patients with advanced, metastatic, or relapsed rare ovarian cancers (like clear cell, low grade serous, granulosa cell, and other subtypes) can access these treatments based on their oncologist’s judgement and the best clinical evidence. No more crushing out-of-pocket costs of $100,000+ per course. Eligible patients now pay just $25 per script (or $7.70 concession) – the same as for common cancers! Prescribing is based on your oncologist’s clinical judgement and the best evidence – […]

$205,000 Raised to Accelerate Rare Ovarian Cancer Research at Hudson Institute

Together, we’re driving hope for females with rare ovarian cancer. ROC Inc Donates $205,000 to Hudson Institute for Rare Ovarian Cancer Research Another major milestone in our ongoing support. Rare Ovarian Cancer Incorporated (ROC Inc) is proud to announce a new donation of $205,000 to the Hudson Institute of Medical Research, supporting vital research into ovarian granulosa cell tumours (GCT) — both adult and juvenile. This latest contribution marks another major milestone in our ongoing support, demonstrating the dedication of our community and our commitment to driving research forward for rare ovarian cancers. Together, these funds reflect the strength of […]

Ride for Research 2024: Join the Cause Today!

Ride for Research 2024 is an upcoming event for ROC Inc and lead by board member Peter Reaburn. The event aims to raise vital funds and awareness for rare ovarian cancer research. The team of 30 riders will cycle for over five consecutive days starting from March 18th, 2024 in Bright Victoria. Currently, they have raised $83,000 out of their $200,000 goal with only 70 days left. Donating to one of the riders and providing words of encouragement is a great way to show support and make a difference. Join the cause and help make a positive impact!

ROC Inc Ride 4 Research March 18-22 March 2024 Call out for riders to join in

Come join our unique event in beautiful Bright, Victoria 18-22 March 2024. An unforgettable experience! This ride is not only about the joy of cycling, but also about supporting a meaningful cause to raise money to support rare ovarian cancer awareness and research. Choose to do a challenging road ride one day, a scenic rail trail the next. The choice is yours. Check out our website for details: https://www.rocinc.org.au/ride-for-research/ The 2024 ROC Inc Ride 4 Research raises money for Rare Ovarian Cancer awareness and research Together, we are raising funds to make a positive impact in our community and beyond. […]

Expressing Gratitude to the Lakeview Hotel Motel and Our Patrons for Supporting ROC Inc.

We extend our sincere gratitude to the Lakeview Hotel Motel and its patrons who are members and have pledged their community points to ROC Inc. By simply being a member, you can earn community points every time you visit. Thus far, members have pledged over $7,000, and we cannot thank you enough. Please note that the current period for pledging your points to ROC Inc will end on December 24th. Join us in supporting ovarian cancer research and awareness by pledging to ROC Inc. If you are not already a member, sign up at the Lakeview Hotel and become a […]

Rare Ovarian Cancer researchers and consumers work together to produce a research paper.

Congratulations to ALL of the authors, lead author Professor Victoria White from Deakin University, Professor Peter Fuller, Associate Professor Simon Chu, Maria Alexiadia, All from the Hudson Institute of Medical Research, Professor Thomas Jobling from Monash Health, Members from the GCT Survivor Sister Facebook Group our Founder and CEO of ROC Inc Natasha Armour (from Australia), Linda Langdale (from the UK), Sue Rogers, Kaye Ackermann and Kim Eroh (all from the USA), on having your research paper published in the journal Cancer – an international interdisciplinary journal of the American Cancer Society https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34767 You should ALL feel proud of your […]